Fennec Pharmaceuticals Inc., a biopharmaceutical company, focuses on cancer therapeutics. Product Candidates The company’s main product candidates, both of which are in the clinical stage of development are as follows: Sodium Thiosulfate (STS) – a water soluble thiol compound that acts as a chemical reducing agent is in two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. Eniluracil (EU) - an oral irreversible dihydropyrimidine dehydrogenase (DPD) inhibitor is the enzyme responsible for rapidly breaking down 5-FU, which completed a Phase II clinical trial in metastatic breast cancer in 2013. Sodium Thiosulfate (STS) The company has licensed from Oregon Health & Science University (OHSU) intellectual property rights for the use of STS as a chemoprotectant, and is in the process of developing STS as a protectant against the hearing loss often caused by platinum-based anti-cancer agents in children. The company has received Orphan Drug Designation in the United States for the use of STS in the prevention of platinum-induced ototoxicity in pediatric patients. STS has been studied by cooperative groups in two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. SIOPEL 6 In 2007, the company announced that its collaborative partner, the International Childhood Liver Tumour Strategy Group, known as SIOPEL, a multi-disciplinary group of specialists under the umbrella of the International Society of Pediatric Oncology, had launched a randomized Phase III clinical trial (SIOPEL 6) to investigate whether STS reduces hearing loss in children receiving cisplatin, a platinum-based chemotherapy often used in pediatric oncology. COG ACCL0431 In 2008, the company announced the activation of a Phase III trial with STS to prevent hearing loss in children receiving cisplatin-based chemotherapy in collaboration with the Children’s Oncology Group (COG ACCL0431). The goal of this Phase III study is to evaluate in a multi-centered, randomized trial whether STS is an effective and safe means of preventing hearing loss in children receiving cisplatin-based chemotherapy for newly diagnosed germ cell, liver (hepatoblastoma), brain (medulloblastoma), nerve tissue (neuroblastoma) or bone (osteosarcoma) cancers. Intellectual Property The company owns 23 issued patents world-wide and the company has 14 patents pending throughout the world. With regards to STS, the company has licensed from Oregon Health and Science University one U.S. and nine foreign patents, with an additional one patent pending. In regards to Eniluracil, the company has been issued 13 patents and is prosecuting 13 additional patents. Research and Development The company’s research and development expenses totaled $0.4 million for the year ended December 31, 2014. History Fennec Pharmaceuticals Inc. was founded in 1996. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in 2014. It was incorporated under the Canada Business Corporations Act in 1996.
fennec pharmaceuticals inc (FRX:Toronto)
68 TW Alexander Drive
PO Box 13628
Research Triangle Park, NC 27709
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for FRX.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact FENNEC PHARMACEUTICALS INC, please visit www.fennecpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.